الفهرس | Only 14 pages are availabe for public view |
Abstract Hemodialysis patients are at an increased risk of acquiring hepatitis B virus (HBV) infection. However, the prevalence of viral hepatitis infection and its genotype distribution among hemodialysis patients are unclear. The study aimed to follow up the immune response to vaccination of HBV among pediatric patients on regular hemodialysis. The present study was carried out at the pediatric hemodialysis unit in Ain Shams university Children’s hospital during the period extending from January 2014 to December 2014 .It included all the patients with ESRD on regular hemodialysis who received HBV vaccination in the Pediatric Dialysis Unit. All the patients were subjected to thorough medical history and examination. The laboratory investigation included complete blood picture (CBC), prothrombin and partial thromboplastin time, liver function tests (ALT, AST, TSB, DSB, Alb), serum iron, ferritin and total iron binding capacity. HBsAb titre by ELISA technique after 6 and 12 months from last vaccination dose. The study included forty patients who are divided randomly into two groups: Group 1: include 19 patients who received three doses of HBV vaccine at 0, 1 and 2 months schedule. - 57 - summary Group 2: include 21 patients who received three doses of HBV vaccine at 0, 1 and 6 months schedule. There was non statistically significant increase of the titer between 6 month and one year readings in group Ӏ and in group II. All patients with ESRD on regular hemodialysis in both groups were found to be immune-protected to HBV after 6 and 12 months from last vaccination dose. |